Spindle Cell Sarcoma

News alerts, weekly reports and conference planners

Related cancers:

NF1 mutation + CDKN2A deletion + CDKN2B deletion + MTAP deletion	Neurofibrosarcoma	NF1 mutation + CDKN2A deletion + CDKN2B deletion + MTAP deletion	Neurofibrosarcoma	MRTX1719 Sensitive: C4 – Case Studies Cancer Discov - 4 weeks (New C4) MRTX1719 Sensitive : C4 Cancer Discov - 4wk	MRTX1719 Sensitive: C4 – Case Studies Cancer Discov - 4 weeks MRTX1719 Sensitive : C4 Cancer Discov - 4 weeks - (New C4)
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Fibrosarcoma	No biomarker	Fibrosarcoma	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
No biomarker	Uterine Corpus Leiomyosarcoma	No biomarker	Uterine Corpus Leiomyosarcoma	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
No biomarker	Fibrosarcoma	No biomarker	Fibrosarcoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	BMIi-1 Sensitive: B - Late Trials BMIi-1 Sensitive : B	BMIi-1 Sensitive: B - Late Trials BMIi-1 Sensitive : B
NTRK1 fusion	Neurofibrosarcoma	NTRK1 fusion	Neurofibrosarcoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
NTRK3 fusion	Neurofibrosarcoma	NTRK3 fusion	Neurofibrosarcoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
NTRK1 fusion	Spindle Cell Sarcoma	NTRK1 fusion	Spindle Cell Sarcoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
NTRK3 fusion	Spindle Cell Sarcoma	NTRK3 fusion	Spindle Cell Sarcoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
BRAF V600E	Neurofibrosarcoma	BRAF V600E	Neurofibrosarcoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
NTRK3 fusion	Fibrosarcoma	NTRK3 fusion	Fibrosarcoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK2 fusion	Fibrosarcoma	NTRK2 fusion	Fibrosarcoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK1 fusion	Fibrosarcoma	NTRK1 fusion	Fibrosarcoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
BRAF V600E	Synovial Sarcoma	BRAF V600E	Synovial Sarcoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
CTAG1B expression	Synovial Sarcoma	CTAG1B expression	Synovial Sarcoma	TBI-1301 Sensitive: C2 – Inclusion Criteria TBI-1301 Sensitive : C2	TBI-1301 Sensitive: C2 – Inclusion Criteria TBI-1301 Sensitive : C2
KRAS G12V	Spindle Cell Sarcoma	KRAS G12V	Spindle Cell Sarcoma	BAL3833 Sensitive: C3 – Early Trials BAL3833 Sensitive : C3	BAL3833 Sensitive: C3 – Early Trials BAL3833 Sensitive : C3
AKT1 E17K	Uterine Corpus Leiomyosarcoma	AKT1 E17K	Uterine Corpus Leiomyosarcoma	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
SMARCB1 negative	Spindle Cell Sarcoma	SMARCB1 negative	Spindle Cell Sarcoma	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3
Chr amplification(4)(q22.1)	Leiomyosarcoma	Chr amplification(4)(q22.1)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(3)(q14.2)	Leiomyosarcoma	Chr del(3)(q14.2)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(11)(q25)	Leiomyosarcoma	Chr del(11)(q25)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(2)(q14.1)	Leiomyosarcoma	Chr del(2)(q14.1)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(2)(p12)	Leiomyosarcoma	Chr del(2)(p12)	Leiomyosarcoma	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3
Chr del(1)(q44)	Leiomyosarcoma	Chr del(1)(q44)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3

Spindle Cell Sarcoma

Associations(100)

Associations
(100)